Acumen Pharmaceuticals (ABOS) Free Cash Flow (2020 - 2026)

Acumen Pharmaceuticals has reported Free Cash Flow for 7 years, with the latest figure at -$24.1 million in Q1 2026.

• Quarterly Free Cash Flow rose 29.45% year-over-year to -$24.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$105.6 million (down 2.92% YoY) and the FY2025 annual result came in at -$115.6 million, down 34.09% from the prior year.
• Free Cash Flow retreated to -$24.1 million in Q1 2026 per ABOS's latest filing, from -$19.1 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$6.5 million in Q2 2022 and troughed at -$34.2 million in Q1 2025.
• A 5-year average of -$17.9 million and a median of -$16.6 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow tumbled 250.55% in 2022, then rose 29.83% in 2025.
• Over 5 years, Free Cash Flow stood at -$11.2 million in 2022, then gained by 25.89% to -$8.3 million in 2023, then plunged by 226.79% to -$27.2 million in 2024, then grew by 29.83% to -$19.1 million in 2025, then slipped by 26.35% to -$24.1 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$24.1 million, -$19.1 million, and -$30.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.